Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors.
Sotheara MoeungChristine ChevreauSabrina MarsiliChristophe MassartAude FléchonRémy DelvaGwenaëlle GravisJean-Pierre LotzJacques-Olivier BayMarine Gross-GoupilThomas FilleronCaroline DelmasThierry LafontÉtienne ChatelutFabienne ThomasPublished in: Pharmaceutical research (2020)
The present study suggests that neither a priori dose individualization nor dose adaptation using TDM is required validating body surface area dosing of etoposide in the TI-CE protocol.